317 related articles for article (PubMed ID: 28398242)
1. Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?
Teschke R; Schulze J; Eickhoff A; Danan G
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28398242
[TBL] [Abstract][Full Text] [Related]
2. Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use.
Teschke R; Danan G
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446036
[TBL] [Abstract][Full Text] [Related]
3. Idiosyncratic Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI): Diagnostic Algorithm Based on the Quantitative Roussel Uclaf Causality Assessment Method (RUCAM).
Teschke R; Danan G
Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33800917
[TBL] [Abstract][Full Text] [Related]
4. Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method.
Teschke R; Méndez-Sánchez N; Eickhoff A
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563242
[TBL] [Abstract][Full Text] [Related]
5. Molecular Idiosyncratic Toxicology of Drugs in the Human Liver Compared with Animals: Basic Considerations.
Teschke R
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047633
[TBL] [Abstract][Full Text] [Related]
6. Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch?
Danan G; Teschke R
Drug Saf; 2018 Aug; 41(8):735-743. PubMed ID: 29502198
[TBL] [Abstract][Full Text] [Related]
7. Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993-Mid 2020: A Comprehensive Analysis.
Teschke R; Danan G
Medicines (Basel); 2020 Sep; 7(10):. PubMed ID: 33003400
[No Abstract] [Full Text] [Related]
8. Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019.
Teschke R
Front Pharmacol; 2019; 10():730. PubMed ID: 31396080
[TBL] [Abstract][Full Text] [Related]
9. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method.
Teschke R
Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1169-1187. PubMed ID: 30354694
[TBL] [Abstract][Full Text] [Related]
10. Utility of Lymphocyte Transformation Test for Assisting Updated Roussel Uclaf Causality Assessment Method in Drug-Induced Liver Injury: A Case-Control Study.
Rodríguez A; García-García I; Martínez de Soto L; Gómez López De Las Huertas A; Borobia AM; González-Torbay A; Akatbach-Bousaid I; González-Muñoz M; Ramírez E
Front Pharmacol; 2022; 13():819589. PubMed ID: 35370653
[No Abstract] [Full Text] [Related]
11. Roussel Uclaf Causality Assessment Method for Drug-Induced Liver Injury: Present and Future.
Danan G; Teschke R
Front Pharmacol; 2019; 10():853. PubMed ID: 31417407
[TBL] [Abstract][Full Text] [Related]
12. RUCAM in Drug and Herb Induced Liver Injury: The Update.
Danan G; Teschke R
Int J Mol Sci; 2015 Dec; 17(1):. PubMed ID: 26712744
[TBL] [Abstract][Full Text] [Related]
13. A revised electronic version of RUCAM for the diagnosis of DILI.
Hayashi PH; Lucena MI; Fontana RJ; Bjornsson ES; Aithal GP; Barnhart H; Gonzalez-Jimenez A; Yang Q; Gu J; Andrade RJ; Hoofnagle JH
Hepatology; 2022 Jul; 76(1):18-31. PubMed ID: 35014066
[TBL] [Abstract][Full Text] [Related]
14. [Carefully reviewing the history of diagnostic scales and paying more attention to the diagnostic value of Roussel - Uclaf causality assessment method scale for drug - induced liver injury].
Chen CW
Zhonghua Gan Zang Bing Za Zhi; 2016 Nov; 24(11):801-803. PubMed ID: 27978922
[TBL] [Abstract][Full Text] [Related]
15. Herb-induced liver injury (HILI) with 12,068 worldwide cases published with causality assessments by Roussel Uclaf Causality Assessment Method (RUCAM): an overview.
Teschke R; Eickhoff A; Schulze J; Danan G
Transl Gastroenterol Hepatol; 2021; 6():51. PubMed ID: 34423172
[TBL] [Abstract][Full Text] [Related]
16. Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM.
Scalfaro E; Streefkerk HJ; Merz M; Meier C; Lewis D
Drug Saf; 2017 Aug; 40(8):715-727. PubMed ID: 28508325
[TBL] [Abstract][Full Text] [Related]
17. A detection algorithm for drug-induced liver injury in medical information databases using the Japanese diagnostic scale and its comparison with the Council for International Organizations of Medical Sciences/the Roussel Uclaf Causality Assessment Method scale.
Hanatani T; Sai K; Tohkin M; Segawa K; Kimura M; Hori K; Kawakami J; Saito Y
Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):984-8. PubMed ID: 24596340
[TBL] [Abstract][Full Text] [Related]
18. Highlights of the drug-induced liver injury literature for 2021.
Woo SM; Alhaqqan DM; Gildea DT; Patel PA; Cundra LB; Lewis JH
Expert Rev Gastroenterol Hepatol; 2022 Aug; 16(8):767-785. PubMed ID: 35839342
[TBL] [Abstract][Full Text] [Related]
19. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.
Rockey DC; Seeff LB; Rochon J; Freston J; Chalasani N; Bonacini M; Fontana RJ; Hayashi PH;
Hepatology; 2010 Jun; 51(6):2117-26. PubMed ID: 20512999
[TBL] [Abstract][Full Text] [Related]
20. Causality assessment for suspected DILI during clinical phases of drug development.
Regev A; Seeff LB; Merz M; Ormarsdottir S; Aithal GP; Gallivan J; Watkins PB
Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S47-56. PubMed ID: 25352327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
